Search

Displaying results 2911 - 2920 of 7503 in total
  1. Drug

    Pozelimab

    go.drugbank.com/drugs/DB15218
    ApprovedInvestigational

    [L47850] In August 18, 2023, pozelimab was approved by the FDA for the treatment of CHAPLE disease. It is currently the only treatment explicitly indicated for CHAPLE disease.[L47875] … [L47880] The pathophysiology of this disease is mainly attributed to the deficiency of the CD55 protein, which is the main regulator of the complement cascade.[A261105,A261110,A261115].

  2. Drug

    Icosapent ethyl

    go.drugbank.com/drugs/DB08887
    ApprovedInvestigationalNutraceutical

    FDA approved on July 26, 2012. … It is used as an adjunct therapy for severe hypertriglyceridemia (TG levels > 500 mg/dL) and to reduce the risk of cardiovascular events in certain patients with elevated triglycerides.

  3. Drug

    Travoprost

    go.drugbank.com/drugs/DB00287
    ApprovedInvestigational

    It is used to decrease intraocular pressure in open-angle glaucoma and ocular hypertension.

  4. Drug

    Trimethaphan

    go.drugbank.com/drugs/DB01116
    ApprovedInvestigational

    A nicotinic antagonist that has been used as a ganglionic blocker in hypertension, as an adjunct to anesthesia, and to induce hypotension during surgery.

  5. Drug

    Tocopherol

    go.drugbank.com/drugs/DB11251
    ApprovedInvestigational

    When the carbons at position 5- and 7- are not methylated, they can function as electrophilic centers that can trap reactive oxygen and nitrogen species. … The classification of the tocopherol molecules is designated depending on the number and position of the methyl substituent in the chromanol ring.

  6. Drug

    Sulfadimethoxine

    go.drugbank.com/drugs/DB06150
    ApprovedVet approvedWithdrawn

    It is widely available in Russia as an over-the-counter drug manufactured by a number of Russian pharmaceutical companies. … In the US, sulfadimethoxine is one of the products that have been withdrawn or removed from the market after being found to be unsafe or not effective.[L43942]

    Synonyms: N(1)-(2,6-Dimethoxy-4-pyrimidinyl)sulfanilamide, 4-amino-N-(2,6-dimethoxy-4-pyrimidinyl)benzenesulfonamide
  7. Drug

    Alaproclate

    go.drugbank.com/drugs/DB13233
    Experimental

    Alaproclate was developed as one of the first selective serotonin reuptake inhibitor (SSRI) antidepressants by Astra AB (now AstraZeneca) in the 1970s. … Alaproclate has also been found to act as a non-competitive NMDA receptor antagonist although without discriminative stimulus properties similar to phencyclidine.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  8. Drug

    Hydroxyethyl cellulose

    go.drugbank.com/drugs/DB11602
    Approved

    It is used as a key ingredient in many household cleaning products, lubricants and cosmetics due to its non-ionic and water-soluble nature. … It is often used as an ingredient in ophthalmic pharmaceutical preparations such as artificial tear solutions and adjunct agent in topical drug formulations to facilitate the delivery of drugs with hydrophobic

  9. Drug

    Mezlocillin

    go.drugbank.com/drugs/DB00948
    Approved

    Semisynthetic ampicillin-derived acylureido penicillin. It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections.

  10. Drug

    Brepocitinib

    go.drugbank.com/drugs/DB15003
    ApprovedInvestigational

    [L64097] Brepocitinib is not recommended in combination with other JAK inhibitors, other TYK2 inhibitors, or biologic DMARDs. … Brepocitinib is an oral Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibitor used to treat dermatomyositis in adults.